Recruiting
Phase 3

Elismetrep

Sponsor:

TriGemX Bio, Inc.

Code:

NCT07816367

Conditions

Migraine

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Elismetrep

Placebo

Study Details

Brief summary:

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.

Conditions

Migraine

Study ID

NCT07816367

Start date

Oct 2, 2026

Status verified date

Oct, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Oct, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1\. Be a male or female, age 18 to 75 years, inclusive, at the time of signing informed consent.

2\. Has greater than a one-year history of migraine with or without aura as defined by International Headache Society criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the patient's medical records from his/her treating physician or with pharmacy records confirming use of a migraine-specific medication (e.g. triptan, gepant, ditan) for > 1 year, and confirmed by the investigator. 3. Has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the 2 months prior to screening (Visit 1). 4. Meet the following requirements:

a. Is a male OR b. Is a female who is of non-childbearing potential defined by at least one of the following criteria: i. Postmenopausal as defined by one of the following:

1. A minimum of 12 months of spontaneous amenorrhea or
2. A minimum of 6 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone level > 40 mIU/mL or
3. At least 6 weeks post bilateral oophorectomy (with or without hysterectomy). OR ii. Post hysterectomy or bilateral salpingectomy, based on the subject's recall of their medical history OR c. Is a female of reproductive potential and: i. Agrees to remain abstinent from heterosexual activity\* OR ii. Agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the End of Study visit.

Acceptable methods of birth control are:

1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal).
2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; or implantable).
3. Intrauterine device (IUD);
4. Intrauterine hormone-releasing system (IUS);
5. Bilateral tubal occlusion;
6. Vasectomized partner;
7. Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action;
8. Male or female condom with or without spermicide;
9. Cap, diaphragm or sponge with spermicide;
10. A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods). \* Abstinence can be used as the sole method of contraception if it is in line with the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

5\. Voluntarily agrees to participate in the study by giving written informed consent. 6. Is able to read, understand and complete the study questionnaires and eDiary. 7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions. 8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion Criteria:

Patients are excluded from the trial if any of the following criteria apply:

1. Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the study. Note: Female participants of child-bearing potential must have a negative serum pregnancy test (β-human chorionic gonadotropin) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

Migraine history-related
2. Has difficulty distinguishing his/her migraine attacks from tension-type headaches.
3. Has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours.
4. Has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the 3 months prior to screening (Visit 1).
5. Has brainstem (also known as basilar-type) or hemiplegic migraine headache, or retinal migraine.
6. Was >50 years old at age of first migraine onset.
7. Is taking migraine prophylactic medication where the prescribed dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

Medical history related
8. Has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia, or significant neurological disorders other than migraine \[Patients who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study\].
9. Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Patients must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.
10. Has a recent history (within the past 3 years of the screening visit) or current diagnosis or evidence of endocrine, hematological, immunological (including Sjogren's syndrome), renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases or hepatic impairment that, per the investigator's judgement, may jeopardize the subject's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.
12. Has a history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke or transient ischemic attack during the 6 months prior to screening.
13. Has a history of human immunodeficiency virus disease.
14. Has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

Laboratory, vital sign, and electrocardiogram related
15. Has a positive test result at screening for hepatitis B surface antigen, hepatitis C virus antibody.
16. Has a screening estimated glomerular filtration rate estimated with the Modification of Diet in Renal Disease (MDRD) equation of <30 mL/min/1.73 m2.
17. Has a screening result for alanine aminotransferase or aspartate aminotransferase of >2.0 X upper limit of normal (ULN) or total bilirubin >1.5 X ULN at the Screening visit. Note: An isolated bilirubin >1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin is within the laboratory normal range.
18. Has a mean value for triplicate corrected QT interval to Fridericia's formula (QTcF) >450 ms for males and >470 ms for females at screening.
19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg measured after at least 5 minutes at rest at the Screening Visit. Note: If a participant's blood pressure is exclusionary on the first triplicate assessment at the Screening Visit, they may have one repeat triplicate blood pressure assessment at that visit after another rest of at least 10 minutes.

Medication use and substance abuse related
20. Has known history of or suspected abuse of alcohol or recreational drugs at Screening.
21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.
22. Has a positive drug screen at screening. Note:

1. If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g., for insomnia) and confirmatory documentation is obtained from the prescribing physician.
2. If amphetamines are detected on the drug screen, this is not exclusionary if the participant is taking a stimulant medication for a therapeutic purpose (e.g., Adderall for attention deficit hyperactivity disorder), confirmatory documentation is obtained from the prescribing physician, and the stimulant medication in question is known to be detected as amphetamine on the drug screen being used.
23. Is currently in violation of study requirements for prohibited and permissible concomitant medications or treatments (not already specified in other criteria) or is anticipated to violate these requirements during study participation (detailed in the protocol).
24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.
25. Has a history of use of ergotamine medications ≥10 days per month on a regular basis for ≥3 months prior to screening.
26. Has a history of non-narcotic analgesic intake ≥15 days per month for ≥3 months prior to screening.

Other
27. Has known or suspected hypersensitivity to trial product(s) or related products.
28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.
29. Has any surgery scheduled for the duration of the trial.
30. Has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females) or has a known hemoglobinopathy (e.g., sickle cell anemia, hemolytic anemia).
31. Has previous participation in this trial. Participation is defined as signed informed consent.
32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g., antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening or ever signed an informed consent for Study K-304 P003. Note: Patients may not be screened at more than one trial site for this study.
33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.
34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site. Note: Rescreening/retesting is not permitted unless specified above.

Study Design

Enrollment

1500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Elismetrep 10 mg

Participants received a single dose of elismetrep 10 mg

experimental: Elismetrep 20 mg

Participants received a single dose of elismetrep 20 mg

placebo comparator: Placebo

Participants received a single dose of placebo

Interventions

Elismetrep

Administered orally

Placebo

Administered orally

Primary outcome measure

  • Pain freedom at 2 hours post-dose [ Time Frame: Two hours post-dose ]
  • Freedom from most bothersome symptoms (MBS) at 2 hours post-dose [ Time Frame: Two hours post-dose ]

Central Contacts and Locations

Central contacts

Locations

Velocity Clinical Research, Phoenix

Recruiting

Phoenix, Arizona, United States, 85006

Contacts

IMA Clinical Research - Phoenix

Recruiting

Phoenix, Arizona, United States, 85012

Contacts

Preferred Research Partners, Inc.

Recruiting

Little Rock, Arkansas, United States, 72211

Contacts

Alliance Research Institute, Canoga Park

Recruiting

Canoga Park, California, United States, 91304

Contacts

Velocity Clinical Research, Chula Vista

Recruiting

Chula Vista, California, United States, 91911

Contacts

Ark Clinical Research, Fountain Valley

Recruiting

Fountain Valley, California, United States, 92708

Contacts

Neurology Center of North Orange County

Recruiting

Fullerton, California, United States, 92835

Contacts

Axiom Research, Los Angeles LLC

Recruiting

Glendale, California, United States, 91206

Contacts

Long Beach Clinical Trials Services, Inc

Recruiting

Long Beach, California, United States, 90806

Contacts

Accellacare - Long Beach

Recruiting

Long Beach, California, United States, 90807

Contacts

Elizabeth Zarate-Rowell

562-492-9966Ezrtrials@gmail.com

Alliance Research Institute, Lynwood

Recruiting

Lynwood, California, United States, 90262

Contacts

Pasadena Clinical Trials

Recruiting

Pasadena, California, United States, 91101

Contacts

Paradigm Clinical Research Centers, LLC

Recruiting

Redding, California, United States, 96001

Contacts

Paradigm Clinical Research Centers, LLC

Recruiting

San Diego, California, United States, 92108

Contacts

Optimus Medical Group

Recruiting

San Francisco, California, United States, 94102

Contacts

Paragon Rx Clinical

Recruiting

Santa Ana, California, United States, 92703

Contacts

Velocity Clinical Research, Van Nuys

Recruiting

Van Nuys, California, United States, 91606

Contacts

Paradigm Clinical Research Centers, LLC; Aurora

Recruiting

Aurora, Colorado, United States, 80012

Contacts

Ki Health Partners, LLC

Recruiting

Stamford, Connecticut, United States, 06905-1206

Contacts

Velocity Clinical Research, Hallandale Beach

Recruiting

Hallandale, Florida, United States, 33009

Contacts

Clinical Research of Central Florida

Recruiting

Lakeland, Florida, United States, 33805

Contacts

AppleMedical Research Group, LLC

Recruiting

Miami, Florida, United States, 33155

Contacts

Sensible Healthcare, LLC

Recruiting

Ocoee, Florida, United States, 34761

Contacts

Clinical Associates of Orlando, LLC

Recruiting

Orlando, Florida, United States, 32819

Contacts

Cenexel Tampa FL

Recruiting

Tampa, Florida, United States, 33613

Contacts

Premiere Research Institute at Palm Beach Neurology

Recruiting

West Palm Beach, Florida, United States, 33407

Contacts

Clinical Integrative Research Center of Atlanta

Recruiting

Atlanta, Georgia, United States, 30328

Contacts

Evergreen Clinical Trials

Recruiting

Norcross, Georgia, United States, 30092

Contacts

Velocity Clinical Research, Savannah

Recruiting

Savannah, Georgia, United States, 31406

Contacts

Paradigm Clinical Research Centers, LLC

Recruiting

Boise, Idaho, United States, 83709

Contacts

Clinical Investigation Specialists, Inc.

Recruiting

Gurnee, Illinois, United States, 60031

Contacts

Evanston Premier Healthcare Research, LLC

Recruiting

Skokie, Illinois, United States, 60077

Contacts

DM Clinical Research, Indianapolis

Recruiting

Indianapolis, Indiana, United States, 46254

Contacts

Indiana Medical Research Institute

Recruiting

Merrillville, Indiana, United States, 46410

Contacts

Accellacare - McFarland |

Recruiting

Ames, Iowa, United States, 50010

Contacts

Velocity Clinical Research, Sioux City

Recruiting

Sioux City, Iowa, United States, 51106

Contacts

NECCR PrimaCare Research, LLC

Recruiting

Fall River, Massachusetts, United States, 02721

Contacts

Neurology Center of New England P.C.

Recruiting

Foxborough, Massachusetts, United States, 02035

Contacts

Montana Medical Research, Inc

Recruiting

Missoula, Montana, United States, 59808

Contacts

Velocity Clinical Research, Norfolk

Recruiting

Norfolk, Nebraska, United States, 68701

Contacts

Quality Clinical Research, Inc.

Recruiting

Omaha, Nebraska, United States, 68114

Contacts

Oasis Clinical Research

Recruiting

Las Vegas, Nevada, United States, 89121

Contacts

Bio Behavioral Health

Recruiting

Toms River, New Jersey, United States, 08755

Contacts

Accellacare - Cary (Cary Medical Group)

Recruiting

Cary, North Carolina, United States, 27518

Contacts

West Clinical Research

Recruiting

Morehead City, North Carolina, United States, 28557

Contacts

Accellacare - Raleigh (Raleigh Medical Group, P.A.)

Recruiting

Raleigh, North Carolina, United States, 27609

Contacts

Accellacare - Wilmington

Recruiting

Wilmington, North Carolina, United States, 28401

Contacts

Accellacare - Winston-Salem

Recruiting

Winston-Salem, North Carolina, United States, 27103

Contacts

Lillestol Research

Recruiting

Fargo, North Dakota, United States, 58104

Contacts

Velocity Clinical Research, Cleveland

Recruiting

Beachwood, Ohio, United States, 44122

Contacts

Velocity Clinical Research, Cincinnati, Blue Ash

Recruiting

Blue Ash, Ohio, United States, 45242

Contacts

Headache Center of Hope

Recruiting

Cincinnati, Ohio, United States, 45236

Contacts

Centricity Research; Columbus, Ohio

Recruiting

Columbus, Ohio, United States, 43213

Contacts

Velocity Clinical Research, Providence

Recruiting

Providence, Rhode Island, United States, 02818

Contacts

Velocity Clinical Research, Anderson

Recruiting

Anderson, South Carolina, United States, 29621

Contacts

Velocity Clinical Research, Gaffney

Recruiting

Gaffney, South Carolina, United States, 29340

Contacts

Central Texas Clinical Research

Recruiting

Austin, Texas, United States, 78705

Contacts

Gadolin Research, LLC

Recruiting

Beaumont, Texas, United States, 77702

Contacts

Velocity Clinical Research, Dallas

Recruiting

Dallas, Texas, United States, 75230

Contacts

Epic Medical Research - DeSoto

Recruiting

DeSoto, Texas, United States, 75115

Contacts

Newco 3A Researh LLC, DBA 3A Research

Recruiting

El Paso, Texas, United States, 79902

Contacts

Red Star Research

Recruiting

Lake Jackson, Texas, United States, 77566

Contacts

Clinical Trials of Texas, LLC, A Flourish Research Site

Recruiting

San Antonio, Texas, United States, 78229

Contacts

San Antonio Clinical Trials

Recruiting

San Antonio, Texas, United States, 78240

Contacts

DM Clinical Research, Sugar Land

Recruiting

Sugar Land, Texas, United States, 77479

Contacts

DM Clinical Research, Tomball

Recruiting

Tomball, Texas, United States, 77375

Contacts

Wasatch Clinical Research, LLC

Recruiting

Salt Lake City, Utah, United States, 84107

Contacts

Highland Clinical Research

Recruiting

Salt Lake City, Utah, United States, 84124

Contacts

More Information

Sponsor

TriGemX Bio, Inc.

Last update posted

Nov 12, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by TriGemX Bio, Inc. on 2026-11-12. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.